FIXX News and Press, Homology Medicines Inc. From 04/04/19

BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today preclinical data demonstrating that HMI-102, its gene therapy candidate for the treatment of phenylketonuria (PKU), restored the normal phenylalanine meta...

The FDA has signed off on a Phase 1/2 clinical trial, pheNIX, evaluating Homology Medicines' ( FIXX +0.4% ) gene therapy candidate HMI-102 in adults with a rare inherited disorder called phenylketonuria (PKU), referred to as an inborn error of metabolism. More news on: Homology Medicin...

- Phase 1/2 pheNIX Trial Would Represent First PKU Gene Therapy to Enter the Clinic - - Initial Clinical Data Expected by the End of 2019 - BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today ...

Homology Medicines (NASDAQ: FIXX ) has filed a sales agreement with Cowen to sell $100M worth of its common stock. More news on: Homology Medicines, Inc., Healthcare stocks news, Read more ...

BEDFORD, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present during a fireside chat at the Alliance for Regenerative Medicine (ARM) Cell & Gene Therapy Investor Day on M...

The following slide deck was published by Homology Medicines, Inc. in conjunction with this Read more ...

Homology Medicines (NASDAQ: FIXX ): Q4 GAAP EPS of -$0.51 misses by $0.07 . Revenue of $0.98M (+19.5% Y/Y) in-line. Press Release More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news,

- On Track to Enter the Clinic and Report Initial Data from Phase 1/2 PKU Gene Therapy Trial in 2019 - - New Data Supporting HMI-102 IND Package Demonstrates Reduction of Phe Levels in the Brain and an Increase in Neurotransmitter Metabolism - - Established External and Inte...

BEDFORD, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the Cowen and Company 39th Annual Healthcare Conference on March 12, 2019 at 8:00 a.m. ET at the Boston Marriott C...

OrthoPediatrics (NASDAQ: KIDS ) initiated with Outperform rating and $44 (17% upside) price target at JMP Securities. More news on: OrthoPediatrics Corp., Homology Medicines, Kodiak Sciences, Healthcare stocks news, Stocks on the move, , Read more ...